• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:30:32 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care
    Get the next $TLGT alert in real time by email
    SC 13G/A 1 tm214737d37_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C.  20549

     

    SCHEDULE 13G*/

    (Rule 13d-102)    

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Teligent, Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    87960W203

     

    (CUSIP Number)

     

    December 31, 2020

     

    Date of Event Which Requires Filing of the Statement

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)
    x      Rule 13d-1(c)
    ¨       Rule 13d-1(d)

     

     

    */ The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP NO. 87960W203 13G/A Page 2 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    Citadel Advisors LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    0 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%1

     

     

    12.

     

     

    TYPE OF REPORTING PERSON

    IA; OO; HC

     

     

    1The percentages reported in this Schedule 13G/A are based upon approximately 21,754,223 shares of common stock outstanding as of December 24, 2020 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on December 31, 2020).

     

     

     

    CUSIP NO. 87960W203 13G/A Page 3 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    Citadel Advisors Holdings LP

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    0 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

     

     

    12.

     

     

    TYPE OF REPORTING PERSON

    PN; HC

     

     

     

    CUSIP NO. 87960W203 13G/A Page 4 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    Citadel GP LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    0 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

     

     

    12.

     

     

    TYPE OF REPORTING PERSON

    OO; HC

     

     

     

    CUSIP NO. 87960W203 13G/A Page 5 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    Citadel Securities LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    35,583 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

     

     

    12.

     

     

    TYPE OF REPORTING PERSON

    BD, OO

     

     

      

    CUSIP NO. 87960W203 13G/A Page 6 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    CALC IV LP

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    35,583 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

     

     

    12.

     

     

    TYPE OF REPORTING PERSON

    PN; HC

     

     

     

    CUSIP NO. 87960W203 13G/A Page 7 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    Citadel Securities GP LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    35,583 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

     

     

    12.

     

     

    TYPE OF REPORTING PERSON

    OO; HC

     

     

     

    CUSIP NO. 87960W203 13G/A Page 8 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    Kenneth Griffin

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S. Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    35,583 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.2%

     

     

    12.

     

     

    TYPE OF REPORTING PERSON

    IN; HC

      

     

     

    CUSIP No. 87960W203 13G/A Page 9 of 14 Pages

     

    Item 1(a)Name of Issuer
     Teligent, Inc.

     

    Item 1(b)Address of Issuer’s Principal Executive Offices
     105 Lincoln Avenue, Buena, New Jersey 08310

     

    Item 2(a)Name of Person Filing
    This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), CALC IV LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to shares of common stock of the above-named issuer owned by Citadel Securities.
      
     CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
      
     The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

     

    Item 2(b)Address of Principal Business Office
    The address of the principal business office of each of the Reporting Persons is 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois 60603.

     

    Item 2(c)Citizenship
    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.

     

    Item 2(d)Title of Class of Securities
    Common stock, par value $0.001 per share

     

    Item 2(e)CUSIP Number
    87960W203

     

     

     

    CUSIP No. 87960W203 13G/A Page 10 of 14 Pages

     

    Item 3If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Exchange Act;

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Exchange Act;

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Exchange Act;

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act;

     

    (e)¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j)¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     

     

    CUSIP No. 87960W203 13G/A Page 11 of 14 Pages

     

    Item 4Ownership

     

    A.Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC

     

    (a)Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 0 shares of common stock.

     

    (b)The number of shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 0% of the common stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 0

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 0

     

    B.Citadel Securities LLC

     

    (a)Citadel Securities LLC may be deemed to beneficially own 35,583 shares of common stock.

     

    (b)The number of shares that Citadel Securities LLC may be deemed to beneficially own constitutes approximately 0.2% of the common stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 35,583

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 35,583

     

    C.CALC IV LP and Citadel Securities GP LLC

     

    (a)Each of CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own 35,583 shares of common stock.

     

    (b)The number of shares that each of CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes approximately 0.2% of the common stock outstanding.

     

     

     

    CUSIP No. 87960W203 13G/A Page 12 of 14 Pages

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 35,583

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 35,583

     

    D.Kenneth Griffin

     

    (a)Mr. Griffin may be deemed to beneficially own 35,583 shares of common stock.

     

    (b)The number of shares that Mr. Griffin may be deemed to beneficially own constitutes approximately 0.2% of the common stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 35,583

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 35,583

     

     

     

    CUSIP No. 87960W203 13G/A Page 13 of 14 Pages

     

    Item 5Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ý.

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person
     Not Applicable

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company
     See Item 2 above

     

    Item 8Identification and Classification of Members of the Group
     Not Applicable

     

    Item 9Notice of Dissolution of Group
     Not Applicable

     

    Item 10Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 87960W203 13G/A Page 14 of 14 Pages

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated this 16th day of February, 2021.

     

    CITADEL SECURITIES LLC   CITADEL ADVISORS LLC
             
    By: /s/ Guy Miller   By: /s/ Gregory Johnson
      Guy Miller, Authorized Signatory     Gregory Johnson, Authorized Signatory

     

     

    CALC IV LP   CITADEL ADVISORS HOLDINGS LP
             
    By: /s/ Guy Miller   By: /s/ Gregory Johnson
      Guy Miller, Authorized Signatory     Gregory Johnson, Authorized Signatory

     

     

    CITADEL SECURITIES GP LLC   CITADEL GP LLC
             
    By: /s/ Guy Miller   By: /s/ Gregory Johnson
      Guy Miller, Authorized Signatory     Gregory Johnson, Authorized Signatory

     

     

        KENNETH GRIFFIN
             
          By: /s/ Gregory Johnson
            Gregory Johnson, attorney-in-fact*

     

     

    *             Gregory Johnson is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Jaws Acquisition Corp. on February 1, 2021.

     

     

    Get the next $TLGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLGT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Benesch Joseph

    3 - Teligent, Inc. (0000352998) (Issuer)

    10/8/21 4:31:06 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form 3 filed by new insider Lozynski Alyssa

    3 - Teligent, Inc. (0000352998) (Issuer)

    10/7/21 11:09:36 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Celentano John E

    4 - Teligent, Inc. (0000352998) (Issuer)

    7/22/21 5:04:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $TLGT
    SEC Filings

    View All

    Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process

    BUENA, N.J., Oct. 14, 2021 /PRNewswire/ -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company ("Teligent" or the "Company"), today announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware to pursue a sale process that is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several interested parties. The Company expects to consummate a sale of the entire busi

    10/14/21 6:15:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

    –Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number  (201) 689-8263 International Number  Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge

    8/16/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

    BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T

    8/11/21 4:05:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form 25-NSE filed by Teligent, Inc.

    25-NSE - Teligent, Inc. (0000352998) (Subject)

    10/27/21 9:46:36 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Teligent, Inc. (0000352998) (Filer)

    10/15/21 4:35:51 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. filed SEC Form 8-K: Leadership Update

    8-K - Teligent, Inc. (0000352998) (Filer)

    9/27/21 5:02:29 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Leadership Updates

    Live Leadership Updates

    View All

    Teligent Announces Hiring of Chief Financial Officer

    BUENA, N.J., April 15, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT) ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced the hiring and appointment of Ernest R. De Paolantonio as Chief Financial Officer of the Company, effective April 15, 2021. Timothy B. Sawyer, President and CEO of the Company, commented, "We are very pleased that Ernie has agreed to join our Teligent team. Over the last several months, we have made key additions to our leadership team, and the appointment of Ernie to the CFO position reflects our commitment to bring in highly talented and experienced individuals who have a strong track record of success. E

    4/15/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors

    BUENA, N.J., Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors, effective immediately. Mr. Pate will serve on the Audit and Nominating and Corporate Governance Committees. Mr. Pate leads a family-owned investment firm and serves on the Board of Directors at multiple companies, including Global Step and Advanced Emissions Solutions, Inc. He excels at leading companies through moments of change to drive business objectives and redefine their possibilities for growth.    John Celentano, Chairman of Teligent's Board of Dire

    2/23/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors

    BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries. John Celentano, Chairman of Teligent's Board of Directors, commented on the appointment, stating that "We are excited to have Bill join Teligent's Board of Directors. He is a strategic leader with extensive experience in helping businesses transform and

    2/16/21 7:30:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Teligent, Inc. (0000352998) (Subject)

    2/16/21 4:30:32 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Teligent, Inc. (0000352998) (Subject)

    2/16/21 12:02:06 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G filed

    SC 13G - Teligent, Inc. (0000352998) (Subject)

    2/16/21 10:39:59 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    $TLGT
    Financials

    Live finance-specific insights

    View All

    Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update

    –Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number  (201) 689-8263 International Number  Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge

    8/16/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021

    BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T

    8/11/21 4:05:00 PM ET
    $TLGT
    Major Pharmaceuticals
    Health Care

    Teligent, Inc. Announces First Quarter 2021 Earnings Report and Provides Business Update

    –Continued Remediation Progress Being Made–Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021–Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard Time –Dial in: (800) 708-4540 US Toll Free Number  (847) 619-6397 US Number  Confirmation Number: 50161966 BUENA, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and provided a business update. "As we prepare for the second half of 2021, we are pleased with the progress being made with respect to remediation, our strengthened capital position, and the recent

    5/25/21 7:00:00 AM ET
    $TLGT
    Major Pharmaceuticals
    Health Care